Where Does Endometrial Cancer Usually Start? Understanding Its Origins and Early Signs

Imagine Sarah, a woman in her late 50s, noticing a persistent, unusual discharge. It wasn’t painful, and it didn’t seem like a major issue at first. She brushed it off, thinking it was just a normal part of aging or perhaps related to hormonal changes. But when it continued for weeks, accompanied by a subtle but growing discomfort, she finally decided to see her doctor. This cautious step, prompted by a seemingly minor symptom, could be crucial, because understanding where endometrial cancer usually starts is the first step toward early detection and effective treatment. For many, the answer to “Where does endometrial cancer usually start?” is more straightforward than they might initially think, and pinpointing its origin within the uterus is key to grasping the nuances of this common gynecologic malignancy.

So, to answer that primary question directly: Endometrial cancer usually starts in the endometrium, which is the inner lining of the uterus. This lining is a dynamic tissue that undergoes monthly changes in response to a woman’s menstrual cycle, preparing for a potential pregnancy. When pregnancy doesn’t occur, this lining is shed, resulting in menstruation. However, when abnormal cell growth occurs within this specialized lining, it can develop into cancer. This is why it’s often referred to as uterine cancer, though it’s important to distinguish it from other types of uterine cancers that might arise in the muscular wall (myometrium) or the cervix.

My own journey into understanding gynecologic cancers, like many others, began with a blend of academic curiosity and a profound desire to demystify complex medical topics for a general audience. I’ve spoken with countless individuals who grapple with uncertainty and fear when faced with a diagnosis or even the possibility of such a condition. The language of medicine can be daunting, and clear, accessible information is paramount. When we talk about “where endometrial cancer usually starts,” we’re really talking about the very fabric of a woman’s reproductive health, the innermost layer of an organ deeply connected to identity and life itself. This isn’t just a scientific question; it’s a human one, and by breaking it down, we can empower individuals with knowledge.

The Endometrium: A Closer Look at the Cancer’s Starting Point

To truly appreciate where endometrial cancer begins, we must first understand the endometrium itself. This remarkable tissue lining the uterus is a complex, hormonally responsive layer. It’s composed of glandular cells and stroma (connective tissue) and is divided into two sublayers: the basal layer and the functional layer. The functional layer is the one that proliferates and then sheds during menstruation.

The endometrium’s health and behavior are intricately linked to the balance of hormones, primarily estrogen and progesterone. Estrogen stimulates the growth and thickening of the endometrium, while progesterone prepares it for implantation and, if pregnancy doesn’t occur, helps stabilize and eventually shed the lining. This delicate hormonal dance is central to a woman’s reproductive life, and disruptions in this balance can create an environment where precancerous changes, and eventually cancer, might develop.

Think of it like a garden. The endometrium is the soil, constantly being prepared and renewed. Estrogen is like the sun, encouraging growth, and progesterone is like the rain and nutrients that nurture it and then signal when it’s time for the cycle to reset. If the sun shines too intensely without adequate regulation, or if certain weeds (abnormal cells) start to sprout and are left unchecked, the garden can become unhealthy.

When endometrial cancer originates, it typically starts as a precancerous condition known as endometrial hyperplasia. This is a condition where the endometrium becomes abnormally thick due to an overgrowth of its cells. Hyperplasia can be further classified as simple or complex, and with or without atypic cellular changes (atypia). Atypia is a critical marker, indicating that the cells are beginning to look abnormal under a microscope and have a higher risk of progressing to cancer.

The vast majority of endometrial cancers are adenocarcinomas, meaning they arise from glandular cells. These are the cells responsible for secreting substances, and in the endometrium, they play a role in the cyclical changes. When these glandular cells undergo malignant transformation, they begin to divide uncontrollably, forming a tumor within the endometrial lining.

Understanding the Types of Endometrial Cancer

While the endometrium is the common starting point, it’s important to note that there are different types of endometrial cancer, which can influence prognosis and treatment. The most common type, accounting for about 80% of cases, is Endometrioid Adenocarcinoma. This type typically develops in women with prolonged exposure to estrogen without a balancing effect from progesterone, often associated with conditions like obesity, polycystic ovary syndrome (PCOS), or the use of unopposed estrogen therapy.

Other, less common types include:

Serous Adenocarcinoma: This is a more aggressive type of endometrial cancer, often found in older women. It tends to spread more quickly and is associated with a poorer prognosis. It’s histologically similar to ovarian serous cancer and is often treated similarly.
Clear Cell Adenocarcinoma: Another aggressive subtype, often linked to prior exposure to diethylstilbestrol (DES) in utero, though this is less common now.
Mucinous Adenocarcinoma: A rare type characterized by the production of mucin.
Undifferentiated Carcinoma: This is a very aggressive cancer where the cells lose their resemblance to normal endometrial cells.

The classification of the cancer’s type and grade (how abnormal the cells look and how quickly they are likely to grow and spread) is a crucial part of the diagnostic process, guiding the treatment plan. For instance, the presence of atypia during a biopsy is a significant indicator that precancerous changes are present and require close monitoring or intervention.

Risk Factors and Early Warning Signs: Connecting the Dots

Understanding where endometrial cancer starts also leads us to consider why it starts in some women and not others. While the exact cause is complex and multifactorial, certain risk factors significantly increase a woman’s likelihood of developing this cancer. Many of these factors are related to hormonal imbalances, particularly an excess of estrogen relative to progesterone.

Key risk factors include:

Age: The risk of endometrial cancer increases with age, with most cases diagnosed after menopause.
Obesity: Fat tissue converts androgens into estrogen, leading to higher estrogen levels. This is a significant risk factor, especially after menopause.
Never having been pregnant (nulliparity): Pregnancy exposes a woman to progesterone, which can have a protective effect.
Early onset of menstruation (before age 12) or late onset of menopause (after age 55): This increases the total number of ovulatory cycles and thus estrogen exposure over a lifetime.
Polycystic Ovary Syndrome (PCOS): This condition is often associated with irregular ovulation and anovulatory cycles, leading to prolonged estrogen stimulation without progesterone.
Diabetes: Especially type 2 diabetes, which is often linked to obesity.
Hypertension (High Blood Pressure): The exact mechanism isn’t fully understood, but it’s an associated risk factor.
Tamoxifen therapy: This drug, used to treat breast cancer, can act like estrogen in the uterus, increasing the risk of endometrial cancer.
Hormone Replacement Therapy (HRT): Using estrogen-only HRT after menopause significantly increases the risk. Combination HRT (estrogen and progesterone) generally carries a lower risk.
Family history of endometrial or other gynecologic cancers: Particularly Lynch syndrome (also known as hereditary nonpolyposis colorectal cancer or HNPCC), which increases the risk of several cancers, including endometrial cancer.

Recognizing these risk factors is important for both individuals and healthcare providers. If a woman falls into a high-risk category, she might benefit from more frequent screenings or a heightened awareness of potential symptoms.

And this brings us to the crucial aspect of early detection: the signs and symptoms. Because endometrial cancer starts in the lining, the most common early symptom is abnormal vaginal bleeding. This is often the “loudest” signal the body sends, and it’s vital not to ignore it, especially for postmenopausal women.

Common signs and symptoms include:

Vaginal bleeding after menopause: This is the most common symptom and should always be investigated promptly. Even a small amount of spotting can be significant.
Bleeding between periods (intermenstrual bleeding) in premenopausal women: While often caused by benign conditions, persistent or unusual bleeding should be checked.
Unusual vaginal discharge: This may be watery, bloody, or have a foul odor.
Pelvic pain or cramping: This symptom is less common in early stages but can occur.
Pain during intercourse.
Unexplained weight loss.
Fatigue.

It’s important to reiterate that these symptoms can also be caused by less serious conditions, such as uterine fibroids, polyps, or infections. However, because of the potential for endometrial cancer, any persistent or concerning symptom warrants a visit to a healthcare provider, ideally a gynecologist. The earlier these symptoms are evaluated, the higher the chance of detecting cancer at its earliest, most treatable stages.

The Diagnostic Journey: From Suspicion to Confirmation

When a woman presents with concerning symptoms, particularly postmenopausal bleeding, her doctor will likely initiate a diagnostic process to determine the cause. The journey often begins with a thorough medical history, focusing on the symptoms, menstrual history, reproductive history, and any known risk factors. A physical examination, including a pelvic exam, will be performed to assess the reproductive organs.

The next crucial step is often an endometrial biopsy. This procedure aims to obtain a tissue sample from the endometrium for microscopic examination by a pathologist. There are several ways this can be done:

Endometrial Biopsy in the Office: This is typically performed without anesthesia or with local anesthesia. A thin, flexible tube called a pipelle is inserted through the cervix into the uterus. Suction is applied to withdraw a small sample of the endometrial lining. This procedure is relatively quick and well-tolerated by most women.
Dilation and Curettage (D&C): If the endometrial biopsy is inconclusive or if more tissue is needed, a D&C might be performed. This procedure is usually done under anesthesia. The cervix is dilated, and a surgical instrument called a curette is used to scrape tissue from the uterine lining. The scraped tissue is then sent to the lab for analysis.

If the biopsy reveals endometrial hyperplasia with atypia or endometrial cancer, further tests will be necessary to determine the extent of the cancer (staging). This helps in planning the most effective treatment.

Imaging tests may include:

Transvaginal Ultrasound: This is often one of the first imaging tests used, especially for postmenopausal bleeding. It can visualize the thickness of the endometrium. A thickened endometrium may be a sign of hyperplasia or cancer.
MRI (Magnetic Resonance Imaging) or CT (Computed Tomography) scan: These scans can provide more detailed images of the uterus and surrounding organs, helping to assess the depth of tumor invasion and whether the cancer has spread to lymph nodes or other parts of the body.
Chest X-ray or PET scan: These may be used to check for metastasis (spread) to distant organs like the lungs or other sites.

Blood tests, such as a cancer antigen 125 (CA-125) level, might also be ordered, although CA-125 is not specific to endometrial cancer. Surgical staging, which involves removing the uterus (hysterectomy), ovaries, fallopian tubes, and nearby lymph nodes, is often performed to accurately determine the stage of the cancer and to treat it.

The Role of Hormones: A Deeper Dive

The interplay of hormones, particularly estrogen and progesterone, is fundamental to understanding where and why endometrial cancer develops. Estrogen’s role in stimulating endometrial growth is a double-edged sword. While essential for the menstrual cycle and reproduction, prolonged or unopposed estrogen exposure without the balancing influence of progesterone can lead to abnormal proliferation of endometrial cells. This is the basis for many of the risk factors we discussed.

Consider a woman with PCOS. Her irregular or absent ovulation means her body doesn’t regularly release progesterone to counteract the effects of estrogen. This chronic estrogenic stimulation can cause the endometrium to thicken excessively and persistently, increasing the risk of atypia and ultimately cancer. Similarly, obesity contributes to higher estrogen levels because adipose (fat) tissue is a site where androgens are converted into estrogen, especially after menopause when the ovaries cease producing significant amounts of hormones.

The concept of “unopposed estrogen” is key here. When estrogen stimulates the endometrium to thicken, progesterone’s role is to stabilize this growth and prepare the tissue for shedding. If progesterone is absent or insufficient, the estrogenic stimulus continues unchecked, leading to abnormal cell growth and potentially cancer. This is why hormone replacement therapy (HRT) prescriptions are carefully considered. Estrogen-only HRT for postmenopausal women significantly raises endometrial cancer risk. However, when progesterone is included in the HRT regimen (combination HRT), it helps to protect the endometrium by inducing regular shedding or by causing atrophic changes, thereby reducing the risk.

Even tamoxifen, a drug used to prevent or treat breast cancer, can have an estrogen-like effect on the endometrium, increasing the risk. This is why women on tamoxifen may require regular monitoring of their uterus. The focus on hormones highlights the endocrine system’s profound influence on reproductive health and the development of certain cancers.

Prevention Strategies: Empowering Women’s Health

Given that endometrial cancer usually starts in the endometrium and is strongly linked to hormonal factors and lifestyle, several preventive strategies can be employed, particularly for those at higher risk. While not all cases can be prevented, understanding and implementing these measures can significantly reduce the likelihood of developing the disease.

Key preventive measures include:

Maintaining a Healthy Weight: This is perhaps one of the most impactful preventive strategies. Losing excess weight, especially after menopause, can reduce the amount of estrogen produced by fat tissue, thereby lowering the risk. A balanced diet and regular physical activity are crucial for weight management.
Managing Diabetes and Hypertension: Effectively controlling these chronic conditions can indirectly reduce the risk of endometrial cancer by addressing underlying metabolic and cardiovascular health factors often associated with hormonal imbalances.
Careful Consideration of Hormone Therapy: For women undergoing hormone replacement therapy after menopause, it is crucial to discuss the risks and benefits with their doctor. Using combination HRT (estrogen and progesterone) is generally preferred over estrogen-only therapy to protect the endometrium. Shortest possible duration and lowest effective dose should be used.
Contraception Choices: Oral contraceptives (birth control pills) that contain both estrogen and progestin can actually reduce the risk of endometrial cancer. The longer a woman uses these pills, the lower her risk. This protective effect can last for many years after stopping the pills.
Awareness of Family History: Women with a family history of endometrial cancer, ovarian cancer, or colorectal cancer (especially if Lynch syndrome is suspected) should inform their doctors. Genetic counseling and testing may be recommended to identify inherited predispositions.
Regular Gynecological Check-ups: While not a direct preventive measure for cancer development, regular check-ups allow for early detection of precancerous conditions like endometrial hyperplasia and prompt management. Discussing any unusual symptoms with your doctor is paramount.

It’s important to note that these are general recommendations. An individual’s risk profile is unique, and personalized advice from a healthcare professional is always best.

Understanding Staging and Treatment: What Happens Next?

Once endometrial cancer is diagnosed, determining its stage is critical. Staging describes the extent of the cancer, including its size, location, and whether it has spread to other parts of the body. The most common staging system used is the International Federation of Gynecology and Obstetrics (FIGO) staging system, which is based on surgical findings.

The stages are generally as follows:

Stage I: The cancer is confined to the uterus.
- Stage IA: Cancer is limited to the endometrium.
- Stage IB: Cancer has invaded the inner half of the myometrium.
Stage II: The cancer has spread to the cervix (cervical stroma).
Stage III: The cancer has spread outside the uterus but has not spread to distant organs. This can involve the parametrium, vagina, lymph nodes, or adnexa.
Stage IV: The cancer has spread to distant organs, such as the bladder, bowel, lungs, liver, or bone.

Treatment for endometrial cancer depends heavily on the stage, grade, and type of cancer, as well as the patient’s overall health and menopausal status. The primary treatment for most stages of endometrial cancer is surgery.

Common treatment modalities include:

Hysterectomy: Surgical removal of the uterus. This is the cornerstone of treatment.
Bilateral Salpingo-oophorectomy: Surgical removal of both fallopian tubes and ovaries. This is often done along with a hysterectomy, especially in postmenopausal women, to remove organs that could potentially be affected by cancer or produce hormones that fuel its growth.
Lymph Node Dissection: Removal of nearby lymph nodes to check for cancer spread. This is a crucial part of surgical staging, particularly for higher-grade or more advanced cancers.
Radiation Therapy: This uses high-energy rays to kill cancer cells. It may be used after surgery to reduce the risk of recurrence, or as a primary treatment if surgery is not possible. External beam radiation or brachytherapy (internal radiation) may be employed.
Chemotherapy: This uses drugs to kill cancer cells. It is typically used for more advanced or aggressive types of endometrial cancer, or when cancer has spread to distant sites.
Hormone Therapy: For certain types of endometrial cancer, particularly those that are hormone-receptor positive, medications that block or alter hormone activity may be used.
Targeted Therapy: Newer treatments that target specific molecular abnormalities in cancer cells.

Treatment decisions are highly individualized and are made by a multidisciplinary team of healthcare professionals, including gynecologic oncologists, radiation oncologists, and medical oncologists.

Personal Reflections and Authoritative Insights

Reflecting on the question “Where does endometrial cancer usually start?” brings to mind the intricate biological processes occurring within the female body. It’s a testament to the delicate balance of hormones that govern our reproductive health. My own exploration into this topic has reinforced the profound importance of listening to our bodies. Sarah’s story, though a hypothetical example, resonates with the real-life experiences of many women who have navigated the early stages of this cancer by paying attention to subtle changes.

Research published in leading journals, such as the *American Journal of Obstetrics & Gynecology* and the *Journal of Clinical Oncology*, consistently highlights the link between hormonal imbalances, lifestyle factors, and the development of endometrial cancer. For instance, studies on the impact of obesity underscore its role not just as a risk factor, but as an active participant in promoting estrogenic environments conducive to cancer growth. The understanding that fat cells are endocrinologically active, particularly post-menopause, is a significant insight that empowers women to focus on weight management as a proactive health measure.

Furthermore, the advancements in understanding the molecular subtypes of endometrial cancer, as reported by organizations like the National Cancer Institute (NCI) and the American Society of Clinical Oncology (ASCO), are revolutionizing treatment. Identifying specific genetic mutations or protein expressions within tumor cells allows for more personalized and effective therapeutic strategies, moving beyond a one-size-fits-all approach. This evolution in treatment reflects the progress being made in translating research findings into tangible patient benefits.

The emphasis on early detection through symptom awareness cannot be overstated. The American College of Obstetricians and Gynecologists (ACOG) consistently provides guidance emphasizing the importance of investigating abnormal uterine bleeding, particularly in postmenopausal women, as it remains the most common and earliest sign of endometrial cancer. This consistent messaging from authoritative bodies is vital for public health awareness.

Ultimately, understanding where endometrial cancer usually starts is not just about knowing the anatomical location. It’s about recognizing the biological underpinnings, the risk factors that can be modified, and the critical importance of proactive health monitoring and prompt medical attention when warning signs appear. It’s a journey of awareness, empowerment, and continuous learning, both for patients and healthcare providers alike.

Frequently Asked Questions About Endometrial Cancer Origins

What is the endometrium?

The endometrium is the inner lining of the uterus, the muscular organ in a woman’s pelvis where a fetus develops during pregnancy. This lining is specialized tissue that undergoes monthly cyclical changes in response to hormones, particularly estrogen and progesterone, as part of the menstrual cycle. It thickens to prepare for a potential pregnancy, and if pregnancy doesn’t occur, it sheds, resulting in menstruation. The endometrium consists of glandular cells and stroma and is crucial for implantation and supporting a pregnancy.

The cyclical nature of the endometrium is directly tied to a woman’s reproductive health. During the follicular phase of the menstrual cycle, estrogen levels rise, stimulating the endometrium to proliferate, becoming thicker and more vascular. In the luteal phase, progesterone is released, which further matures the endometrium, making it receptive for embryo implantation. If fertilization and implantation do not occur, both estrogen and progesterone levels drop, leading to the breakdown and shedding of the functional layer of the endometrium, which we experience as a menstrual period.

Understanding the endometrium’s function and its hormonal dependency is key to grasping why it is the site where endometrial cancer typically begins. Abnormalities in the hormonal balance, excessive or unopposed estrogen exposure, or genetic predispositions can lead to precancerous changes within this lining, which can then progress to cancer.

Why is abnormal uterine bleeding the most common early symptom of endometrial cancer?

Abnormal uterine bleeding is the most common early symptom of endometrial cancer because the cancer originates in the endometrium, the very lining responsible for menstrual bleeding. As cancer cells grow and multiply within this lining, they disrupt its normal structure and function. This disruption can lead to irregular shedding, bleeding between periods (in premenopausal women), or bleeding after menopause, when menstruation has naturally ceased.

The abnormal cells are more fragile and prone to bleeding than healthy endometrial cells. Furthermore, the uncontrolled growth can lead to areas of necrosis (tissue death) within the tumor, which can also contribute to bleeding. Because the endometrium is richly supplied with blood vessels, any significant abnormality or lesion within it is likely to manifest as bleeding. This symptom is often readily noticeable by patients, making it a critical early warning sign.

It’s crucial to emphasize that while abnormal bleeding is a common symptom, it does not automatically mean cancer is present. Many benign conditions, such as fibroids, polyps, hormonal imbalances, or infections, can also cause abnormal uterine bleeding. However, due to the potential seriousness of endometrial cancer, any unusual bleeding, especially postmenopausal bleeding, should always be promptly evaluated by a healthcare professional to rule out malignancy.

Can endometrial cancer start anywhere else in the uterus?

While endometrial cancer typically starts in the endometrium, it is important to note that other types of cancer can arise in the uterus. Endometrial cancer specifically refers to cancer that begins in the endometrium. However, the uterus also has a muscular wall called the myometrium and is connected to the cervix. Cancer can develop in these other parts of the uterus as well, but these are classified differently.

For example, uterine sarcomas are cancers that arise from the connective tissues or muscles of the uterus, such as the myometrium. These are much rarer than endometrial adenocarcinomas. Cervical cancer, on the other hand, starts in the cervix, the lower, narrow part of the uterus that opens into the vagina. Therefore, when we discuss “endometrial cancer,” we are specifically referring to cancer originating from the inner lining.

The distinction is important because the behavior, symptoms, and treatment of these different uterine cancers can vary significantly. Endometrial cancer, originating from the glandular tissue of the endometrium, has distinct characteristics and risk factors compared to uterine sarcomas, which arise from mesenchymal cells, or cervical cancer, which is often linked to human papillomavirus (HPV) infection.

What is the difference between endometrial hyperplasia and endometrial cancer?

Endometrial hyperplasia is a precancerous condition characterized by the excessive thickening of the endometrium due to an overgrowth of its cells. It is a stage that can, but does not always, precede endometrial cancer. Endometrial cancer, on the other hand, is a malignant tumor that has formed from the cells of the endometrium and has the potential to invade surrounding tissues and spread to other parts of the body.

Hyperplasia is categorized based on its cellular appearance under a microscope. It can be simple or complex, and crucially, it can occur with or without atypia. Simple hyperplasia involves a uniform increase in endometrial glands and stroma. Complex hyperplasia shows more irregular glands. The presence of atypia (atypical hyperplasia) is the most significant factor because these cells are morphologically abnormal and show a much higher risk of progressing to cancer. It is estimated that atypical hyperplasia can progress to endometrial cancer in about 25% to 30% of cases if left untreated.

The key difference lies in the invasiveness and the potential for metastasis. Hyperplasia, even with atypia, is generally confined to the endometrium. Cancer, however, involves cells that have undergone malignant transformation and can break away from the primary site to invade deeper into the uterine wall (myometrium) and spread to lymph nodes or distant organs. Diagnosing hyperplasia accurately, especially differentiating it from cancer, is vital for appropriate management, which might range from close monitoring to hormone therapy or surgical intervention.

How do doctors determine if it’s endometrial cancer or hyperplasia?

Doctors determine whether a condition is endometrial hyperplasia or endometrial cancer through a careful pathological examination of tissue samples obtained from the endometrium. The primary diagnostic tool for this is an endometrial biopsy, which can be performed in a doctor’s office using a thin instrument called a pipelle, or through a Dilation and Curettage (D&C) procedure, which is typically done under anesthesia and involves scraping tissue from the uterine lining.

These tissue samples are then sent to a pathology laboratory, where a pathologist examines them under a microscope. The pathologist looks for several key features:

Cellular Abnormalities (Atypia): The presence and degree of atypia, meaning how abnormal the cells’ appearance is, are critical. Atypical hyperplasia has cells that look somewhat abnormal but are still confined to the glands. Endometrial cancer, however, shows cells that are clearly malignant, often with enlarged, irregular nuclei and increased cell division.
Glandular Architecture: In hyperplasia, the glands may be crowded or irregular in shape. In cancer, the malignant cells often form complex glandular structures or solid nests, and they invade the surrounding stroma.
Invasion: The most definitive sign of cancer is the invasion of the endometrial cells into the underlying myometrium (the muscular wall of the uterus). The pathologist will meticulously examine the tissue to see if the cancer cells have breached the basement membrane of the endometrial glands and invaded the stroma or deeper into the myometrium.
Grade of Cancer: If cancer is present, the pathologist will also determine its grade, which reflects how abnormal the cancer cells look and how quickly they are likely to grow and spread. A well-differentiated cancer (Grade 1) looks more like normal cells, while a poorly differentiated cancer (Grade 3) looks very abnormal and aggressive.

The results of this microscopic examination are what differentiate between hyperplasia and invasive cancer. If cancer is diagnosed, further staging procedures, often including imaging and surgical evaluation, will be performed to determine the extent of the disease.

What are the most significant risk factors for endometrial cancer?

The most significant risk factors for endometrial cancer are those that lead to an imbalance of hormones in the body, particularly prolonged exposure to estrogen without a corresponding adequate level of progesterone. Here are some of the most impactful risk factors:

Age: The risk increases significantly with age, with most cases diagnosed in women over 50, particularly after menopause.
Obesity: This is a major risk factor. Fat tissue (adipose tissue) converts androgens into estrogen, leading to higher circulating estrogen levels, especially after menopause when the ovaries stop producing estrogen. The more overweight a woman is, the higher her risk.
Never having been pregnant (Nulliparity): Pregnancy is associated with progesterone production, which can have a protective effect on the endometrium. Women who have never been pregnant are at higher risk.
Early Menarche or Late Menopause: Starting menstruation at a young age (before 12) or experiencing menopause at an older age (after 55) means a woman has been exposed to estrogen for more years of her life, increasing her risk.
Polycystic Ovary Syndrome (PCOS): PCOS often leads to irregular or absent ovulation (anovulation), meaning women with PCOS do not regularly release progesterone. This results in a prolonged and unopposed estrogenic stimulus on the endometrium.
Diabetes: Particularly type 2 diabetes, which is often associated with obesity and metabolic disturbances that can influence hormone levels.
Tamoxifen Therapy: This drug, used in breast cancer treatment and prevention, can act like estrogen in the uterus, increasing the risk of endometrial cancer.
Hormone Replacement Therapy (HRT): Using estrogen-only HRT after menopause is a known risk factor. Combination HRT (estrogen with progesterone) is generally considered safer for the endometrium.
Family History and Genetic Syndromes: A family history of endometrial or other gynecologic cancers, especially Lynch syndrome (hereditary nonpolyposis colorectal cancer), significantly increases the risk.

While not all risk factors can be changed (like age or genetics), many, such as maintaining a healthy weight, managing diabetes, and discussing HRT with a doctor, are within a woman’s control and can help reduce her risk.

Can menopausal hormone therapy cause endometrial cancer?

Yes, menopausal hormone therapy (MHT), particularly estrogen-only therapy, can increase the risk of endometrial cancer. During menopause, a woman’s ovaries stop producing significant amounts of estrogen. MHT is sometimes prescribed to alleviate menopausal symptoms like hot flashes and vaginal dryness. Estrogen is very effective at relieving these symptoms.

However, estrogen alone stimulates the growth of the endometrium. Without the counterbalancing effect of progesterone, this continuous stimulation can lead to endometrial hyperplasia and, subsequently, endometrial cancer. This is why, for women with a uterus, combination therapy, which includes both estrogen and a progestogen (a synthetic form of progesterone), is generally recommended. The progestogen helps to stabilize and shed the endometrium, or cause it to become inactive, thereby significantly reducing the risk of developing endometrial cancer compared to estrogen-only therapy.

The decision to use MHT should be individualized, weighing the benefits against the risks. Doctors will consider a woman’s personal and family medical history, as well as the duration and dose of therapy. For women who have had a hysterectomy (uterus removed), estrogen-only therapy does not carry an increased risk of endometrial cancer because there is no endometrium to be affected.

Where Does Endometrial Cancer Usually Start? Understanding Its Origins and Early Signs